# Canine Myxomatous Mitral Valve Disease: Staging and Therapy


## Key Takeaways

- Canine Myxomatous Mitral Valve Disease (MMVD) is staged using the ACVIM consensus framework (B1, B2, C, D), correlating with clinical signs, radiographic cardiomegaly (Vertebral Heart Score > 10.5), and echocardiographic left atrial enlargement (LA/Ao ratio > 1.4 for B2).
- Asymptomatic dogs (Stage B1) with no cardiac remodeling do not benefit from early medical intervention, including ACE inhibitors, as evidenced by trials showing no delay in the onset of congestive heart failure (CHF).
- Pimobendan is the cornerstone therapy for Stage B2 dogs (pre-clinical disease with cardiac remodeling) and Stage C dogs (with CHF), demonstrating benefit in delaying CHF onset and improving quality of life, respectively.
- Management of CHF (Stage C/D) involves a multi-modal approach including furosemide for diuresis, ACE inhibitors for neurohormonal blockade, pimobendan for inotropic and vasodilatory support, and often spironolactone for potassium sparing and additional neurohormonal antagonism.
- Monitoring for decompensation in treated dogs relies heavily on owner observation of resting respiratory rate (above 30-40 breaths/min is a critical threshold), body weight changes (3-5% gain suggests congestion), and appetite, necessitating prompt veterinary re-evaluation.
- Recognized complications include refractory pulmonary edema, cardiogenic pulmonary hypertension, atrial fibrillation, and chordae tendineae rupture, each with specific diagnostic indicators (e.g., tricuspid regurgitation velocity for pulmonary hypertension, ECG for AF) and requiring tailored therapeutic escalation.

---

Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disorder in dogs, and the majority of adult dogs develop some degree of valvular degeneration as they age. This article provides a staging-based framework for diagnosis and medical management of MMVD in dogs, written for practicing veterinarians who manage these patients in primary care and specialty settings. The content addresses the clinical question of how to stage disease severity accurately and how to select and monitor therapy at each stage, with emphasis on the evidence supporting current recommendations.

The pathophysiology of MMVD involves progressive remodeling of the mitral apparatus, including expansion of the extracellular matrix with glycosaminoglycans and proteoglycans, alteration of valvular interstitial cells, and attenuation of the collagen-laden fibrosa layer. These changes produce malformation of the mitral apparatus, biomechanical dysfunction, and ultimately mitral incompetence. Mitral regurgitation is the most common manifestation, and in advanced stages the resulting volume overload promotes progressive valvular regurgitation, left atrial and left ventricular remodeling, atrial tears, chordal rupture, and congestive heart failure (CHF). The disease follows a predictable clinical trajectory: many dogs remain asymptomatic for years, but approximately 30% progress to heart failure and eventually die as a consequence of the disease. Left atrial enlargement, particularly a change in left atrial size over time, appears to be the most reliable predictor of progression in some studies, though further work is needed to identify asymptomatic patients at higher risk of developing CHF.

The staging system used throughout this article follows the scheme published by the American College of Veterinary Internal Medicine (ACVIM) consensus statements, which classify MMVD into stages B1, B2, C, and D based on clinical signs, radiographic findings, and echocardiographic parameters. This framework guides therapeutic decisions at each point in the disease course and provides a common language for communication between primary care veterinarians and cardiologists.

## At a Glance

| Parameter | Stage B1 | Stage B2 | Stage C | Stage D |
| --- | --- | --- | --- | --- |
| Clinical signs | None | None | Signs of CHF present | Refractory CHF |
| Murmur intensity | Soft to moderate | Moderate to loud | Loud, often with tachycardia | Loud, variable |
| Left atrial enlargement | Absent | Present | Moderate to severe | Severe |
| Vertebral heart score | Normal | Often > 10.5 | Increased | Markedly increased |
| Primary therapy | Monitoring only | Pimobendan | Pimobendan, furosemide, ACE inhibitor | Intensified diuresis, adjunctive agents |
| Monitoring interval | 6 to 12 months | 6 months | 1 to 3 months | 1 to 4 weeks |

## Natural History and Prognostic Variables

The clinical course of MMVD is highly variable, and accurate prognostication requires integration of clinical and echocardiographic findings. In a retrospective study of 558 dogs with mitral regurgitation of varying severity, median survival time was 19.5 months, and variables associated with shorter survival included age over 8 years, syncope, heart rate above 140 beats per minute, dyspnea, arrhythmias, and higher heart failure class. Echocardiographic predictors included end-systolic volume index above 30 mL/m², left atrial to aortic root ratio (LA/Ao) above 1.7, and E wave transmitral peak velocity above 1.2 m/s. In multivariate analysis, syncope, LA/Ao above 1.7, and E wave velocity above 1.2 m/s remained significant for all-cause mortality, while LA/Ao was the only significant variable for cardiac-related death.

In a separate study of 256 dogs with preclinical MMVD, 27.3% died during the observation period, and the median survival time regardless of cause was 588 days. The presence of a murmur was associated with an increased risk of death, and LA/Ao above 1.4 was the only negative predictor for cardiac-related deaths. Among dogs that were re-examined, 34 progressed to a more advanced stage, and the presence of E wave velocity above 1.2 m/s and cough were significant predictors of progression. These findings support the clinical practice of using left atrial size as a central determinant of staging and therapeutic decisions in asymptomatic dogs.

## Pathologic Basis of Staging

The gross and histopathologic changes of MMVD correlate with disease severity and inform the rationale for staging. Early lesions show focal thickening of the valve leaflets with glycosaminoglycan accumulation, while advanced disease produces diffuse leaflet thickening, chordal elongation or rupture, and annular dilation. The mitral valve apparatus functions as an integrated unit, and competence depends on the complex interplay between the annulus, leaflets, chordae tendineae, papillary muscles, and adjacent myocardium. Disruption of any component can accelerate regurgitation and remodeling.

The clinical relevance of these pathologic changes lies in their hemodynamic consequences. As regurgitant volume increases, the left atrium and left ventricle undergo eccentric remodeling to accommodate the volume overload. This remodeling is initially compensatory but eventually becomes maladaptive, leading to increased wall stress, neurohormonal activation, and progression to CHF. The rate of remodeling varies between individuals, which explains why some dogs remain stable for years while others progress rapidly. Breed differences in disease expression have been documented, with Cavalier King Charles Spaniels and Dachshunds showing high prevalence and heritable patterns of valve prolapse severity.

## Therapeutic Principles and Evidence Base

The goals of therapy differ by stage. For asymptomatic dogs, the primary question is whether any intervention delays the onset of CHF. A prospective, randomized, double-blinded, placebo-controlled multicenter trial evaluated enalapril as monotherapy in 229 asymptomatic Cavalier King Charles Spaniels with mitral regurgitation. The number of dogs developing heart failure was similar between treatment and placebo groups, and the estimated time from initiation of therapy to heart failure did not differ. This trial provides strong evidence that ACE inhibitor monotherapy does not delay progression in preclinical disease, and it supports the current recommendation to withhold therapy in stage B1 patients.

For dogs with overt CHF, medical management with furosemide, an angiotensin-converting enzyme inhibitor, pimobendan, and spironolactone has been associated with acceptable quality of life for a relatively long period. The evidence base for this combination derives from several clinical trials and accumulated clinical experience. Pimobendan is now considered the central element of therapy for stage B2 and stage C disease, though the specific evidence for its use at each stage will be examined in detail in the therapy sections that follow.

## Diagnostic Confirmation and Staging Workup

Accurate staging requires a minimum database that includes a complete physical examination, thoracic radiographs, and echocardiography. The physical examination provides the initial suspicion based on murmur characteriztics, and the presence of a murmur itself carries prognostic significance in preclinical disease. Thoracic radiographs assess cardiomegaly and pulmonary venous congestion, and the vertebral heart score provides a quantitative measure of cardiac size. Echocardiography is essential for confirming the diagnosis, quantifying left atrial enlargement, and assessing systolic function. The LA/Ao ratio measured from the right parasternal short-axis view is the most widely used echocardiographic index for staging decisions.

Electrocardiography is useful for detecting arrhythmias and chamber enlargement, though it is less sensitive than echocardiography for structural assessment. Blood pressure measurement and routine laboratory testing are recommended to identify concurrent conditions that may complicate therapy, particularly in geriatric patients. The ACVIM consensus statements provide the framework for integrating these findings into a stage assignment, and the specific criteria for each stage will be detailed in the staging section of this article.

## Stage-Based Treatment Algorithm

The ACVIM staging system translates directly into therapeutic decisions. Stage A dogs, those with breed predisposition but no detectable disease, require no cardiac medication. Stage B1 dogs, with a murmur but no remodeling, likewise receive no cardiac therapy. The evidence does not support early intervention in these groups. A prospective trial of enalapril in asymptomatic Cavalier King Charles Spaniels with mitral regurgitation found no difference in time to congestive heart failure between treated and placebo groups, with 43% and 42% developing heart failure respectively [efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation](https://pubmed.ncbi.nlm.nih.gov/11822810/). No currently available treatment delays the onset of clinical signs of congestive heart failure in asymptomatic dogs [canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy](https://pubmed.ncbi.nlm.nih.gov/20610017/).

Stage B2 marks the first therapeutic intervention point. Dogs in this stage have significant left atrial and ventricular enlargement but no history of congestive heart failure. The decision to start pimobendan rests on echocardiographic and radiographic thresholds. Left atrial to aortic root ratio greater than 1.4 predicts cardiac-related death in preclinical disease, and this threshold has been adopted as part of the B2 entry criteria [survival characteriztics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration](https://pubmed.ncbi.nlm.nih.gov/22211523/). Vertebral heart score greater than 10.5 on thoracic radiography supports the diagnosis of cardiomegaly. When both criteria are met, pimobendan is initiated. When only one criterion is met, repeat evaluation in 3 to 6 months is reasonable, particularly in breeds predisposed to rapid progression.

Stage C begins with the first episode of congestive heart failure. Therapy expands to include furosemide, pimobendan, and an angiotensin-converting enzyme inhibitor. Spironolactone is added as a fourth agent in most protocols. Dogs with overt congestive heart failure can be managed with acceptable quality of life for a relatively long period using this combination [canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy](https://pubmed.ncbi.nlm.nih.gov/20610017/). Stage D refers to dogs that remain symptomatic despite standard therapy. These dogs require dose escalation, additional diuretic agents, and careful monitoring for adverse effects.

## Pimobendan in Preclinical and Clinical Disease

Pimobendan is a positive inotrope and vasodilator with calcium-sensitizing properties. It is the only drug with demonstrated benefit in delaying the onset of congestive heart failure in stage B2 dogs. The drug is administered at a fixed dose per dog, not a weight-scaled dose, and current formulary references must be consulted for the approved range. Pimobendan is continued indefinitely once started. In stage C and D dogs, pimobendan is typically given twice daily, and dose adjustment is not usually required unless adverse effects develop.

Anorexia and gastrointestinal signs are the most common adverse effects. These are usually transient and resolve within the first week of therapy. Persistent anorexia warrants investigation for concurrent disease or dose reduction. Pimobendan can be given with food to reduce gastrointestinal upset. In dogs with stage D disease, the addition of a second pimobendan dose in the middle of the night may be considered, although this practice is based on clinical experience instead of controlled trial data.

## Diuretic Therapy and Monitoring

Furosemide is the central element of congestive heart failure management. The starting dose depends on the severity of congestion. Dogs with mild pulmonary edema may respond to lower doses, while those with severe respiratory distress require higher initial doses and sometimes parenteral administration. The goal is the lowest dose that maintains the dog free of congestion. Once the dog is stable, the dose is tapered gradually over days to weeks. Many dogs can be maintained on intermittent or reduced dosing, but some require continuous therapy.

Monitoring parameters for furosemide therapy include body weight, renal function, and electrolyte status. Prerenal azotemia is the most common complication. Serum creatinine and blood urea nitrogen should be checked 7 to 14 days after any dose change and then every 3 to 6 months in stable dogs. Potassium and sodium concentrations should be monitored concurrently. Hypokalemia increases the risk of arrhythmias and weakens respiratory muscles. Spironolactone, a potassium-sparing diuretic, mitigates this effect and is recommended in stage C and D disease.

| Monitoring Parameter | Frequency | What It Detects | Action Threshold |
| --- | --- | --- | --- |
| Body weight | Daily during stabilization, then weekly | Fluid accumulation or dehydration | Increase of 3% to 5% suggests congestion |
| Respiratory rate at rest | Twice daily during stabilization | Early pulmonary edema | Sustained rate above 30 to 40 breaths per minute |
| Serum creatinine | 7 to 14 days after dose change, then every 3 to 6 months | Prerenal azotemia from diuresis | Increase of 25% to 50% above baseline warrants dose review |
| Serum potassium | Same schedule as creatinine | Hypokalemia or hyperkalemia | Below 3.5 mmol/L or above 5.5 mmol/L |
| Systolic blood pressure | At each recheck | Hypotension from vasodilators or dehydration | Below 90 to 100 mm Hg warrants dose reduction |

## Cough Management in MMVD

Cough in MMVD has multiple causes, and the treatment differs accordingly. The first step is to determine whether the cough reflects pulmonary edema, airway compression from an enlarged left atrium, or concurrent respiratory disease. Thoracic radiography is essential. Pulmonary edema produces an interstitial to alveolar pattern with a perihilar distribution. Airway compression produces a bronchial pattern or tracheal deviation without alveolar infiltrates. Dogs with chronic bronchitis or tracheal collapse may have both conditions concurrently.

Pulmonary edema responds to diuresis. Cough from airway compression does not respond to furosemide and may worsen with over-diuresis. Antitussive therapy with a centrally acting agent such as butorphanol or hydrocodone may be considered for nonproductive cough that disrupts sleep or quality of life. These agents do not treat the underlying disease and should be used sparingly. Dogs with concurrent respiratory disease may benefit from bronchodilators or corticosteroids, but these agents have no role in uncomplicated MMVD.

A cough that develops in a previously stable dog warrants investigation before dose adjustment. Measure resting respiratory rate at home. A rate consistently above 30 to 40 breaths per minute suggests pulmonary edema. A normal respiratory rate with persistent cough points toward airway disease or compression. Echocardiography can assess left atrial size and identify progressive remodeling. The presence of cough in preclinical disease is a risk factor for progression, with one study reporting a hazard ratio of 7.89 for dogs that coughed at initial examination [survival characteriztics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration](https://pubmed.ncbi.nlm.nih.gov/22211523/).

## Monitoring the Treated Dog

Stable stage C and D dogs should be rechecked every 3 to 6 months. Each recheck includes physical examination, body weight, thoracic auscultation, and assessment of respiratory rate at rest. Serum biochemistry and electrolyte panels are obtained at least twice yearly. Thoracic radiography is repeated when clinical signs change or when dose adjustment is contemplated. Echocardiography is repeated when progression is suspected, but routine serial imaging in stable dogs adds limited information.

Home monitoring by the owner is the most sensitive tool for detecting early decompensation. Resting respiratory rate is the single most useful parameter. Owners should count breaths while the dog sleeps, and a rate above 30 breaths per minute sustained over two consecutive nights warrants veterinary evaluation. Other warning signs include reduced appetite, tachypnea with exercise, and syncope. Syncope in MMVD is a negative prognostic indicator and was significantly associated with survival time in a large cohort study [survival characteriztics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease](https://pubmed.ncbi.nlm.nih.gov/18289298/).

The treatment plan is adjusted based on these findings. Weight gain with elevated respiratory rate suggests fluid retention and warrants furosemide dose increase. Weight loss with azotemia suggests over-diuresis and warrants dose reduction. Hypotension with weakness warrants reduction of vasodilator therapy. Each adjustment should be followed by reassessment within 7 to 14 days.

## Recognized Complications and Early Detection

The principal failure modes in treated MMVD are refractory pulmonary edema, cardiogenic pulmonary hypertension, atrial fibrillation, and chordae tendineae rupture. Each has a characteriztic clinical signature that allows early recognition before decompensation becomes irreversible.

Refractory or recurrent pulmonary edema despite adequate diuretic doses signals either progression of mitral regurgitation or a missed trigger such as dietary sodium indiscretion, intercurrent illness, or owner non-adherence. Serial body weight measurement at each visit is the most sensitive clinic-side tool. A gain of 3% to 5% over the stable baseline weight precedes audible crackles or visible respiratory effort by days. Thoracic radiography should be repeated when weight gain exceeds this threshold, not when tachypnea is already obvious.

Cardiogenic pulmonary hypertension develops as chronic left atrial hypertension transmits backward through the pulmonary vasculature. Clinical clues include a split or accentuated S2, syncope, and exercise intolerance out of proportion to radiographic edema. Echocardiographic estimation of pulmonary arterial pressure from tricuspid regurgitation velocity is the confirmatory test. Dogs with a tricuspid regurgitation velocity above 3.5 m/s warrant additional therapy directed at the pulmonary circulation, but the evidence base for specific pulmonary vasodilators in MMVD-associated pulmonary hypertension remains limited.

Atrial fibrillation is the most common clinically significant arrhythmia in advanced MMVD. It should be suspected when the heart rate is irregularly irregular and rapid, and confirmed by electrocardiography. The onset of atrial fibrillation often precipitates acute congestive failure because the loss of atrial transport and the rapid ventricular rate reduce cardiac output and increase left atrial pressure. Rate control, not rhythm conversion, is the usual therapeutic goal in this disease.

Chordae tendineae rupture presents as acute severe mitral regurgitation with sudden onset tachypnea, weakness, and a new or louder holosystolic murmur. The echocardiographic findings are a flail leaflet segment and a large, eccentric regurgitant jet. This event is a medical emergency and typically requires rapid escalation of diuretic and positive inotropic support.

| Observation | Likely cause | Discriminating check |
|---|---|---|
| Weight gain 3% to 5% over stable baseline | Subclinical pulmonary edema | Thoracic radiography, lung ultrasound |
| Syncope with a split S2 | Pulmonary hypertension | Tricuspid regurgitation velocity on echocardiography |
| Irregularly irregular rapid heart rate | Atrial fibrillation | Electrocardiography |
| Sudden severe tachypnea with louder murmur | Chordal rupture | Echocardiography showing flail leaflet |
| Recurrent edema at stable drug doses | Dietary indiscretion or disease progression | Owner interview, radiography, reassess stage |

## Common Errors and Corrective Actions

The most frequent error in managing preclinical disease is treating the murmur instead of the stage. A dog with a loud murmur but normal left atrial and ventricular dimensions on echocardiography does not benefit from pimobendan, and the available evidence does not support ACE inhibitor therapy in asymptomatic dogs without cardiomegaly. The corrective action is to stage by imaging, not by auscultation.

A second error is attributing every cough to heart failure. In geriatric dogs, airway disease, collapsing trachea, and bronchomalacia are common comorbidities. A cough that is productive, positional, or triggered by excitement or collar pressure is more consistent with airway disease than with pulmonary edema. Radiographic evidence of left atrial enlargement does not prove that the cough is cardiac in origin. The distinction matters because escalating diuretic therapy for a non-cardiac cough risks azotemia and weakness without resolving the sign.

A third error is underdosing furosemide in acute congestive failure out of caution about renal function. In the emergency setting, the priority is relieving pulmonary edema. Renal parameters should be assessed after stabilization, not before initial diuresis. Conversely, chronic over-diuresis with failure to reduce the dose once compensation is achieved produces prerenal azotemia and weakness. The corrective action is a structured taper to the lowest effective maintenance dose with serial renal biochemistry.

A fourth error is discontinuing pimobendan when a dog develops anorexia or gastrointestinal signs. Pimobendan is not a common cause of these signs, and withdrawal in a dog with cardiomegaly can precipitate acute decompensation. The drug should be continued while the gastrointestinal signs are investigated independently.

## Limitations of the Evidence and Areas of Divergent Opinion

The evidence base for MMVD therapy is strongest for pimobendan in stage B2 and for combination therapy in stage C and D. Several areas remain contested. The role of spironolactone in stage B2 is not established by prospective trial data, although it is widely used in clinical heart failure. The optimal timing for initiating spironolactone therefore varies among cardiologists.

The management of cough in stage B2 dogs without echocardiographic criteria for pimobendan is genuinely uncertain. Some clinicians treat symptomatic cough with antitussives or bronchodilators, while others argue that cough in this stage is often non-cardiac and should be managed as primary airway disease. No controlled trial resolves this question.

The value of routine electrocardiography in monitoring treated dogs is debated. Ambulatory monitoring detects more arrhythmias than brief in-hospital recordings, but the prognostic significance of intermittent ventricular arrhythmias in MMVD is not well defined. The ACVIM consensus statements provide staging guidance but do not mandate a specific monitoring interval for arrhythmia surveillance.

## Referral and Escalation Criteria

Referral to a veterinary cardiologist is warranted when echocardiography is needed for accurate staging, when a dog fails to stabilize within 24 to 48 hours of appropriate initial therapy, when atrial fibrillation or complex arrhythmias are detected, or when chordal rupture is suspected. Specialist consultation is also appropriate when the diagnosis is uncertain, for example when a murmur is atypical or when concurrent pulmonary hypertension complicates management.

Laboratory involvement is indicated for monitoring renal function and electrolytes during chronic diuretic therapy, and for assessing thyroid status in older dogs with new or worsening cardiac signs, since hyperthyroidism can exacerbate mitral regurgitation. Regulatory reporting is not generally applicable to MMVD because no reportable infectious or zoonotic disease is involved. The relevant international standards for animal health surveillance do not address degenerative cardiac disease.

## Frequently Asked Questions

### How should I adjust my monitoring plan when echocardiography is unavailable?

When echocardiography is not accessible, staging relies on thoracic radiography, auscultation, and clinical signs. Vertebral heart score provides a repeatable measure of cardiomegaly. Left apical systolic murmurs graded III or higher correlate with significant regurgitation in most breeds. Radiographic left atrial enlargement, pulmonary venous distension, and interstitial or alveolar patterns support progression to congestive heart failure. Serial body weight, respiratory rate at rest, and cough frequency offer practical trend monitoring. The ACVIM consensus framework supports this approach, acknowledging that imaging modality availability varies across practice settings. Refer for echocardiography when clinical progression is suspected but radiographic findings remain equivocal, particularly before initiating or escalating pimobendan therapy.

### What is the role of dietary sodium restriction in dogs already receiving standard therapy?

Dietary sodium restriction is adjunctive, not primary, therapy. Moderate restriction is reasonable once congestive heart failure develops, but extreme restriction can activate neurohormonal pathways and reduce palatability. Commercial cardiac diets provide consistent moderate sodium content and are preferred over homemade diets unless a veterinary nutritionist formulates them. No published trial demonstrates that dietary modification alone delays progression from preclinical to clinical disease. The natural history data indicate that most asymptomatic dogs remain stable for extended periods, and no medical intervention has shown benefit in delaying heart failure onset. For dogs in stage C, sodium restriction complements diuretic and neurohormonal blockade but does not replace dose adjustments of furosemide or pimobendan.

### How do I manage MMVD in a dog with concurrent chronic kidney disease?

Concurrent kidney disease complicates diuretic therapy because azotemia may worsen as renal perfusion falls. Establish baseline creatinine, symmetric dimethylarginine, and urine protein-to-creatinine ratio before initiating furosemide. Start at the lower end of the diuretic range and titrate against clinical signs of congestion while monitoring renal values. Accept mild azotemia if respiratory effort improves and the dog eats and drinks adequately. Spironolactone may be preferred over higher furosemide doses in some cases, though its effect is modest. Pimobendan improves cardiac output and may preserve renal perfusion relative to diuretics alone. Recheck renal parameters within 7 to 10 days of any diuretic dose change. The evidence base for optimal dosing in this combination is limited, and individualised titration guided by serial clinical and laboratory assessment remains essential.

### What should I document in the medical record for a dog started on cardiac therapy?

Record the stage assigned, the criteria supporting that stage, and the specific drugs, doses, and dosing intervals prescribed. Document baseline body weight, heart rate, respiratory rate at rest, murmur grade and point of maximal intensity, and radiographic or echocardiographic measurements. Note owner instructions given, including medication administration technique, expected response timeline, and parameters that should trigger recheck or emergency contact. At each recheck, record the same variables to allow direct comparison. Document any dose adjustments with the reason and the owner-reported response. The ACVIM consensus statements provide a structured staging framework that supports consistent record keeping across visits and between clinicians.

### How should I discuss prognosis with an owner whose dog has just entered stage C?

Frame the discussion around quality of life and expected response to therapy instead of a specific survival time. Explain that most dogs with controlled congestive heart failure maintain acceptable quality of life for months to years with combination medical therapy. Describe the monitoring parameters the owner can track at home, particularly resting respiratory rate, appetite, and willingness to exercise. Clarify that dose adjustments are expected over time and that rechecks will guide those changes. Discuss the financial commitment of ongoing medication and monitoring openly. The published survival data for dogs with clinical disease reflect cohorts managed before some current therapies were widely used, so individual outcomes vary considerably. Offer a recheck schedule and a clear plan for contacting the practice if respiratory effort worsens.

### Does breed affect drug selection or dosing in MMVD?

Breed affects disease prevalence, age of onset, and rate of progression, but not the fundamental drug classes used. Cavalier King Charles Spaniels and Dachshunds develop MMVD earlier and with high prevalence, as documented in epidemiological studies. Larger breeds such as Labrador Retrievers may present with more severe regurgitation at diagnosis. Dosing is weight-based, so a 10 kg Cavalier receives a smaller absolute dose than a 30 kg Labrador, but the per-kilogram dose follows the same reference ranges. Breed-specific differences in drug metabolism are not established for the cardiac drugs used in MMVD. Body condition and lean mass matter more than breed for dose calculations. Consult current formulary references for weight-based dosing and adjust based on clinical response and adverse effects.

## Related Clinical & Scientific Guides

* [Feline Hepatic Lipidosis: Nutritional and Medical Management](/knowledge/veterinary-medicine/clinical-internal-medicine/feline-hepatic-lipidosis-nutritional-medical-management)
* [Canine Respiratory Infection: Diagnostic Approach and Treatment](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-respiratory-infection-diagnostic-approach-treatment)
* [Canine Respiratory Virus: Diagnostic and Management Considerations](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-respiratory-virus-diagnostic-management-considerations)


## References and Further Reading

- [Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy.](https://pubmed.ncbi.nlm.nih.gov/20610017/). 2010.
- [Survival characteriztics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration.](https://pubmed.ncbi.nlm.nih.gov/22211523/). 2012.
- [Survival characteriztics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease.](https://pubmed.ncbi.nlm.nih.gov/18289298/). 2008.
- [Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.](https://pubmed.ncbi.nlm.nih.gov/11822810/). 2002.
- [Epidemiology and inheritance of mitral valve prolapse in Dachshunds.](https://pubmed.ncbi.nlm.nih.gov/10499729/). 1999.
- [Pathology of myxomatous mitral valve disease in the dog.](https://pubmed.ncbi.nlm.nih.gov/22386587/). 2012.
- [ACVIM Consensus Statements](https://www.acvim.org/Animal-Owners/Animal-Education/Consensus-Statements). Journal of Veterinary Internal Medicine.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.

## Related Articles

- [Canine Chronic Kidney Disease: Staging and Therapeutic Plan](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-chronic-kidney-disease-staging-therapeutic-plan)
- [Canine Autoimmune Disease Overview: Diagnostic Considerations](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-autoimmune-disease-overview-diagnostic-considerations)
- [Canine Congestive Heart Failure: Staging and Therapeutic Plan](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-congestive-heart-failure-staging-therapeutic-plan)
- [Canine Gallbladder Disease: Diagnostic and Therapeutic Approach](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-gallbladder-disease-diagnostic-therapeutic-approach)
- [Canine Diabetes Mellitus: Insulin Therapy Adjustment Framework](/knowledge/veterinary-medicine/clinical-internal-medicine/canine-diabetes-mellitus-insulin-therapy-adjustment-framework)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.